Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2022 after the market closes on March 9, 2023. The management team will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss the results. Investors can access the live and recorded webcast on the Company’s website. Iridex specializes in innovative ophthalmic laser-based products for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. Their products are marketed in the U.S. and over 100 countries worldwide.
- Anticipation of complete financial results for Q4 and FY 2022 may boost investor confidence.
- Continued development of innovative laser-based medical products could enhance market position.
- None.
MOUNTAIN VIEW, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and full year 2022 after the close of trading on Thursday, March 9, 2023.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
When will Iridex release its financial results for Q4 2022?
What time is the Iridex conference call scheduled for?
How can investors access the Iridex conference call?
What products does Iridex focus on?
